AzTrials
AzTrials

End Stage Chronic Renal FailureNCT07385651

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

A study testing 10˚C deceased donor kidney storage using Traferox XPort in people with End Stage Chronic Renal Failure and Chronic Kidney Disease (Stages 4 and 5), run by Vanderbilt University Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to test how storage temperature of deceased donor kidneys affects kidney function after transplant in adult patients receiving a kidney transplant. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
10˚C deceased donor kidney storage using Traferox XPort
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
18 Nov 2024to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Participant inclusion criteria

  1. All adult single organ kidney transplant candidates on the waiting list at Vanderbilt University Medical Center (VUMC) will be eligible for enrollment.

Participant exclusion criteria

  1. Kidney transplant candidates less than 18 years old
  2. Kidney transplant candidates that decline consent
  3. Transplant candidates listed for multi-organ transplant

Deceased donor organ inclusion criteria:

  1. Donation after brain death or donation after circulatory death kidney donors, whose health care proxy has consented for donation and the possibility of research
  2. Deceased donor kidneys that have been allocated to VUMC as a primary match offer prior to organ procurement will be eligible

Deceased donor organ exclusion criteria:

  1. Donors whose health care proxy has declined consent for the possibility of research
  2. Deceased donor kidneys that have been allocated to VUMC as a backup offer
  3. Deceased donor kidneys that have been allocated to VUMC as a post procurement offer
  4. Deceased donor kidneys that have already been placed on ice

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

W. Christian Crannell, MD contact

615-322-5000

christian.crannell@vumc.org

United States1 site, 1 recruiting
  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37027

    W. Christian Crannell, MD, 615-322-5000, christian.crannell@vumc.org

    W. Christian Crannell, MD

    Recruiting

Other trials in United States

About this study

The goal of this clinical trial is to test how storage temperature of deceased donor kidneys affects kidney function after transplant in adult patients receiving a kidney transplant.

The main question it aims to answer is:

Read more
  • Do patients that receive a kidney transplant stored at 10 °C have improved post-transplant kidney function? Researchers will compare patients who receive kidneys stored at 10 °C versus kidneys stored at 4°C (on ice, i.e. conventional storage) to see if kidneys stored at 10 °C have improved function.

Participants will:

  • Be made aware of and consent to receive a kidney transplant that had been stored at 10 °C
  • Have their urine collected 24 hours after surgery to be analyzed for research
Read the detailed description

Kidney transplantation is a life-saving treatment for patients with end stage kidney disease, which affects nearly 800,000 patients in the United States. However, deceased donor kidney transplantation is often complicated by delayed graft function (DGF), conventionally defined as the recipient requiring hemodialysis within the first week after transplant. DGF is unfortunately common, occurring in 25% of all transplanted kidneys and portends worse long-term graft survival, higher rates of rejection, and increased recipient mortality. DGF commonly occurs because of ischemic reperfusion injury (IRI), a complex pattern of injury occurring at the time of organ procurement. IRI results from decreased cellular ATP, decreased function of the Na/K pump, mitochondrial destabilization, the generation of reactive oxygen species (ROS), apoptosis, complement and immune cell activation. Most commonly, kidneys and other deceased donor organs have been stored at 4˚C (ie on ice) to minimize cellular oxygen consumption and prevent IRI. However, preliminary data show that porcine kidneys are exposed to high levels of ROS at 4˚C due to decreased mitochondrial protective pathways associated with hypothermic conditions. Promising studies in other organ systems demonstrate reduced ROS when organs are stored at 10˚C instead of on ice. In lung transplant, porcine lungs stored at 10˚C vs ice show better physiologic metrics, decreased mitochondrial DNA release, less cell death, less lactate production, and less glucose consumption. Higher levels of protective mitochondrial metabolites were observed in lungs stored at 10°C than on ice. These metabolites promote the innate anti-oxidative system within mitochondria, protecting against ischemic injury. Clinically, human lung transplant shows favorable clinical outcomes with prolonged cold ischemia at 10˚C vs ice. Within kidney transplant, there have been no similar investigations of 10˚C storage compared to ice. We hypothesize that deceased donor kidney storage at 10˚C will be superior to ice. This study has the potential to transform deceased donor organ storage and establish a new standard of care by storing kidneys at 10˚C. Further, preserving kidney mitochondrial function and decreasing the rate of DGF, would allow transplant centers to accept more organs by lowering the clinical risk associated with organ acceptance, with an overall increase in organ utilization.

Methods Once an organ offer is made to VUMC and reviewed for suitability, the kidney transplant recipient will be contacted by one of our research key study personnel (KSP), trained as kidney transplant organ coordinators to review the organ offer per standard operating procedure. Once the patient has accepted the organ offer, the coordinator will review the study with the patient using the phone script for informed consent.

Organ storage groups: 10˚C vs. ice The study will test the difference between storage of donor kidneys at 10˚C (experimental) and ice storage (standard of care). The storage method used will be determined by the location of the donor kidney because of study logistics (see below).

If the donor kidney is coming from organ procurement organization(s) (OPO) participating in the trial, the study organ coordinator will alert the on-site procurement team that the kidney is to be placed at 10˚C. The organ coordinators have regular and frequent contact with the OPOs as part of the procurement and transplant process. If the donor kidney is outside of a participating OPO, no alert is required. These organs are automatically stored on ice.

All donor kidneys will be obtained per standard clinical practice by the local procurement surgeon. After collection, the kidneys will either a) be placed in a temperature controlled portable cooler and maintained at 10˚C or b) be stored on ice per standard of care procedures. Donor kidneys will be labeled with the anonymous United Network for Organ Sharing number and transported to VUMC.

The kidney transplant will proceed per routine clinical practice at VUMC regardless of storage conditions. Standard VUMC kidney transplant practices and clinical pathways will be followed for each study arm. Immunosuppression protocols will be followed and identical for each arm.

Post operatively, study participants will have their urine collected 24 hours post operatively and analyzed. Routine clinical information will be abstracted from the electronic medical record and used for analysis.

Being tested
10˚C deceased donor kidney storage using Traferox XPort
Keywords
kidney transplant recipients, delayed graft function, ischemia reperfusion injury, 10 Celsius kidney storage
Medical subject headings
Renal Insufficiency, Chronic, Delayed Graft Function, Reperfusion Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 10˚C deceased donor kidney storage using Traferox XPortDevice

    Deceased donor kidneys will be stored using the Traferox XPort device to maintain an organ temperature of 10˚C during storage and transport until the time of transplant

Study groups in NCT07385651
Study groupRoleWhat they receive
10˚C deceased donor kidney storageExperimentalDeceased donor kidneys from participating organ procurement organizations (OPO) will be procured per OPO routine clinical practice and then stored at 10˚C in dedicated temperature controlled coolers until transplant at Vanderbilt University Medical Center. Donor kidneys will be labeled with the anonymous United Network for Organ Sharing number. The transplant will then proceed per routine clinical practice and usual clinical pathways will be followed. Post operatively, study participants will have their urine collected 24 hours post operatively and analyzed. Routine clinical information will be abstracted from the electronic medical record and used for analysis.
Receives: Device: 10˚C deceased donor kidney storage using Traferox XPort
Conventional (ice storage) deceased donor kidney storageNo interventionDeceased donor kidneys, not meeting eligibility for the intervention arm, that are accepted for transplant at Vanderbilt University Medical Center will be procured per routine clinical practice and stored conventionally on ice. Donor kidneys will be labeled with the anonymous United Network for Organ Sharing number. The transplant will proceed per routine clinical practice. Usual clinical pathways will be followed. Post operatively, study participants will have their urine collected 24 hours post operatively and analyzed. Routine clinical information will be abstracted from the electronic medical record and used for analysis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Urine NGAL

    Neutrophil gelatinase-associated lipocalin (NGAL), a urine biomarker for acute kidney injury that has been shown to be predictive of delayed kidney graft function. Urine will be collected after the kidney transplant, processed and stored with an anonymous ID.

    Measured: Urine collected post operatively day one after kidney transplant

Secondary outcomes (3)
  1. Delayed graft function

    Delayed graft function is defined as the patient requiring dialysis within 7 days after kidney transplant.

    Measured: Within 7 days after kidney transplant

  2. Post operative urine output

    Total volume of urine output for the first 24 hours after the kidney transplant

    Measured: 24 hours after kidney transplant

  3. Creatinine and estimated glomerular filtration rate trends

    Participants serum creatinine and estimated glomerular filtration rate trends will be abstracted from the electronic medical record

    Measured: One month post operatively after kidney transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2026
  2. Study start18 Nov 2024
  3. Primary completion1 Jun 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
If the donor kidney is coming from an organ procurement organization(s) (OPO) participating in the trial, the study organ coordinator will alert the on-site procurement team that the kidney is to be placed at 10˚C (the intervention arm). If the donor kidney is outside of a participating OPO these organs are automatically stored on ice (the control arm)
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07385651
Sponsor's protocol ID
241113
Status last verified
Jan 2026
First submitted
23 Jan 2026
Last updated
6 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: This study is committed to promoting transparency and reproducibility in research. Individual Participant Data (IPD) underlying the results reported in this study will be made available upon reasonable request. Requests for access to IPD will be considered on a case-by-case basis, contingent on the provision of a methodologically sound proposal and compliance with ethical guidelines. Data sharing will occur in accordance with applicable privacy regulations, informed consent from participants, and institutional policies. Researchers wishing to access the data should contact the corresponding author. De-identified participant data such as demographic information that was collected as part of the study will be available. Results will be made available.

Questions about this trial

What is this clinical trial studying?

A study testing 10˚C deceased donor kidney storage using Traferox XPort in people with End Stage Chronic Renal Failure and Chronic Kidney Disease (Stages 4 and 5), run by Vanderbilt University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact W. Christian Crannell, MD (615-322-5000, christian.crannell@vumc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Urine NGAL (time frame: Urine collected post operatively day one after kidney transplant). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in